BMY
Bristol-Myers Squibb Company
50.24
USD
This page is just a preview of the data found in TrendSpider’s full version
Bristol-Myers Squibb Company stock is down -4.83% since 30 days ago. The next earnings date is Feb 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 65.96% of the previous 46 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 0% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 04 Dec 17:32 | 16 Jan, 2026 | 55.00 | 485 | ||
| 04 Dec 17:44 | 21 Jun, 2024 | 50.00 | 14548 | ||
| 04 Dec 18:03 | 19 Apr, 2024 | 50.00 | 1154 | ||
| 04 Dec 19:08 | 19 Apr, 2024 | 50.00 | 1154 | ||
| 05 Dec 14:37 | 15 Dec, 2023 | 52.50 | 1572 | ||
| 05 Dec 17:26 | 17 Jan, 2025 | 50.00 | 1663 | ||
| 05 Dec 17:32 | 21 Jun, 2024 | 55.00 | 4600 | ||
| 05 Dec 17:36 | 21 Jun, 2024 | 55.00 | 4600 | ||
| 05 Dec 19:57 | 15 Mar, 2024 | 52.50 | 4284 | ||
| 05 Dec 20:51 | 17 Jan, 2025 | 75.00 | 3651 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma.
